• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Anti-SARS-CoV-2 spike protein S1 receptor-binding domain antibody after vaccination with inactivated whole-virus SARS-CoV-2 in end-stage kidney disease patients: an initial report.

作者信息

Boongird Sarinya, Chuengsaman Piyatida, Phanprasert Salinnart, Kitpermkiat Rungthiwa, Assanatham Montira, Nongnuch Arkom, Kiertiburanakul Sasisopin, Malathum Kumthorn, Phuphuakrat Angsana, Setthaudom Chavachol, Bruminhent Jackrapong

机构信息

Division of Nephrology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

Banphaeo-Charoenkrung Peritoneal Dialysis Center, Banphaeo Dialysis Group, Banphaeo Hospital, Bangkok, Thailand.

出版信息

Kidney Int. 2021 Nov;100(5):1136-1138. doi: 10.1016/j.kint.2021.08.007. Epub 2021 Aug 19.

DOI:10.1016/j.kint.2021.08.007
PMID:34419552
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8375247/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2fe/8375247/b41bf948f5fb/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2fe/8375247/c0f955175121/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2fe/8375247/b41bf948f5fb/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2fe/8375247/c0f955175121/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2fe/8375247/b41bf948f5fb/gr2_lrg.jpg

相似文献

1
Anti-SARS-CoV-2 spike protein S1 receptor-binding domain antibody after vaccination with inactivated whole-virus SARS-CoV-2 in end-stage kidney disease patients: an initial report.终末期肾病患者接种新型冠状病毒灭活全病毒疫苗后抗新型冠状病毒刺突蛋白S1受体结合域抗体：初步报告
Kidney Int. 2021 Nov;100(5):1136-1138. doi: 10.1016/j.kint.2021.08.007. Epub 2021 Aug 19.
2
Non-Receptor-Mediated Lipid Membrane Permeabilization by the SARS-CoV-2 Spike Protein S1 Subunit.SARS-CoV-2 刺突蛋白 S1 亚基介导的非受体脂膜通透性
ACS Appl Mater Interfaces. 2020 Dec 16;12(50):55649-55658. doi: 10.1021/acsami.0c17044. Epub 2020 Dec 3.
3
Static all-atom energetic mappings of the SARS-Cov-2 spike protein and dynamic stability analysis of "Up" versus "Down" protomer states.SARS-CoV-2 刺突蛋白的静态全原子能量映射和“向上”与“向下”构象状态的动态稳定性分析。
PLoS One. 2020 Nov 10;15(11):e0241168. doi: 10.1371/journal.pone.0241168. eCollection 2020.
4
A Barcoded Flow Cytometric Assay to Explore the Antibody Responses Against SARS-CoV-2 Spike and Its Variants.一种带有条形码的流式细胞术检测方法，用于探索针对 SARS-CoV-2 刺突及其变体的抗体反应。
Front Immunol. 2021 Sep 23;12:730766. doi: 10.3389/fimmu.2021.730766. eCollection 2021.
5
SARS-CoV-2 spike produced in insect cells elicits high neutralization titres in non-human primates.昆虫细胞表达的 SARS-CoV-2 刺突蛋白可在非人灵长类动物中引起高中和抗体滴度。
Emerg Microbes Infect. 2020 Dec;9(1):2076-2090. doi: 10.1080/22221751.2020.1821583.
6
Clinical validation of the Siemens quantitative SARS-CoV-2 spike IgG assay (sCOVG) reveals improved sensitivity and a good correlation with virus neutralization titers.西门子定量 SARS-CoV-2 刺突 IgG 检测试剂盒（sCOVG）的临床验证显示出了更高的灵敏度，与病毒中和滴度有良好的相关性。
Clin Chem Lab Med. 2021 Apr 9;59(8):1453-1462. doi: 10.1515/cclm-2021-0214. Print 2021 Jul 27.
7
Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.SARS-COV-2 刺突糖蛋白的优化假型条件。
J Virol. 2020 Oct 14;94(21). doi: 10.1128/JVI.01062-20.
8
Nicotinic Cholinergic System and COVID-19: In Silico Identification of an Interaction between SARS-CoV-2 and Nicotinic Receptors with Potential Therapeutic Targeting Implications.烟碱型乙酰胆碱能系统与 COVID-19：SARS-CoV-2 与烟碱受体相互作用的计算鉴定及其潜在治疗靶点意义。
Int J Mol Sci. 2020 Aug 13;21(16):5807. doi: 10.3390/ijms21165807.
9
In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs.基于 SARS-CoV-2 刺突糖蛋白与 ACE-2 受体同源物和人类 TLR 相互作用的比较特征的计算机研究。
J Med Virol. 2020 Oct;92(10):2105-2113. doi: 10.1002/jmv.25987. Epub 2020 May 17.
10
Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis.慢性透析患者 COVID-19 疫苗接种的免疫原性。
Front Immunol. 2021 Jun 30;12:690698. doi: 10.3389/fimmu.2021.690698. eCollection 2021.

引用本文的文献

1
Determinants of protective humoral response to mRNA-1273 and BNT162b2 vaccines in peritoneal dialysis patients: a prospective cohort study.mRNA-1273 和 BNT162b2 疫苗在腹膜透析患者中诱导保护性体液免疫反应的决定因素：一项前瞻性队列研究。
BMC Nephrol. 2024 Oct 31;25(1):391. doi: 10.1186/s12882-024-03789-3.
2
Vaccination for Patients Receiving Dialysis.接受透析患者的疫苗接种
Kidney Med. 2023 Dec 9;6(3):100775. doi: 10.1016/j.xkme.2023.100775. eCollection 2024 Mar.
3
Outcomes of vaccinations against respiratory diseases in patients with end-stage renal disease undergoing hemodialysis: A systematic review and meta-analysis.
终末期肾病血液透析患者接种呼吸道疾病疫苗的效果：系统评价和荟萃分析。
PLoS One. 2023 Feb 9;18(2):e0281160. doi: 10.1371/journal.pone.0281160. eCollection 2023.
4
Immune response after COVID-19 vaccination among patients with chronic kidney disease and kidney transplant.COVID-19 疫苗接种后慢性肾脏病和肾移植患者的免疫反应。
Vaccine. 2022 Oct 26;40(45):6499-6511. doi: 10.1016/j.vaccine.2022.09.067. Epub 2022 Sep 28.
5
Short-Term Immunogenicity Profiles and Predictors for Suboptimal Immune Responses in Patients with End-Stage Kidney Disease Immunized with Inactivated SARS-CoV-2 Vaccine.终末期肾病患者接种灭活 SARS-CoV-2 疫苗后的短期免疫原性概况及免疫反应欠佳的预测因素
Infect Dis Ther. 2022 Feb;11(1):351-365. doi: 10.1007/s40121-021-00574-9. Epub 2021 Dec 3.